Figure 4. Human CD83 CAR T cells prevent xenogeneic GVHD.

(A) NSG mice received 25 × 10⁶ human PBMCs and were inoculated with low (1 × 10⁶) or high dose (10 × 10⁶) CD83 CAR or (1 × 10⁶ to 10 × 10⁶) mock-transduced T cells. The CARs were autologous to the PBMC donor. An additional control group of mice received PBMCs alone. (A) Survival and (B) GVHD clinical scores are shown. Clinical scores incorporate an aggregate assessment of activity, fur and skin condition, weight loss, and posture. Pooled data from 3 independent experiments, up to 9 mice per experimental arm for survival, with a representative experiment depicting long-term GVHD clinical scores. In separate experiments, recipient mice were humanely euthanized at day +21 and tissue GVHD severity was evaluated by an expert blinded pathologist. Xenogeneic GVHD path scores, representative H&E images, amount of Ki-67⁺ CD3⁺ T cells/HPF, and representative IHC images (CD3, red; Ki-67, brown) are shown for recipient lung (C–F) and liver (G–J). Original magnification, ×100. Pooled data from 2 independent experiments, up to 6 mice per experimental arm. Log-rank test (A), ANOVA (C and G), Mann-Whitney (E and I). **P = 0.001–0.01 and ***P = 0.0001–0.001.